$1.030
-0.010 (-0.96%)終値時点
HCWB のニュース
HCWB のイベント
Selling Stockholders Offer Up to 1.81M Shares of Common Stock
This filing relates to the offer and sale from time to time by the selling stockholders of up to 1.81M shares of common stock. The company is not selling any shares under this prospectus and will not receive any of the proceeds from the sale of shares by the selling stockholders.
HCW Biologics Prices $1.5M Private Placement
HCW Biologics announced the pricing of its $1.5M private placement with an existing stockholder of the company. The company agreed to issue and sell an aggregate of 903,614 units. The combined purchase price for each Unit consisting of a Pre-Funded Warrant and the right to receive one Common Warrant upon, and subject to, stockholder approval of the issuance thereof, was $1.6599 per Unit. Maxim Group is acting as the sole placement agent for the Offering.
HCW Biologics Enters Exclusive Distribution Agreement with Akron Biotech
HCW Biologics announced that the company has entered into an exclusive distribution agreement with Akron Biotech for the commercialization of HCW11-006 for use as a reagent to support a new method of producing highly functional human CAR-T cells for treating cancer, autoimmune disease, and infectious diseases. Akron operates within a highly specialized global network of biomedical institutions, primarily catering to a customer base of advanced therapy developers, biopharmaceutical companies, and research organizations. Akron manufactures and markets cGMP-compliant ancillary materials necessary for bringing regenerative medicine from preclinical stages to commercialization.
HCW Biologics Receives Patent Allowance for HCW9302 in Treating Alopecia Areata
HCW Biologics announced receipt of a Notice of Allowance from the U.S. Patent and Trademark Office for claims directed to use of HCW9302 to treat alopecia areata. Together with four other recently issued patents with claims for broad compositions, nucleic acids encoding for HCW9302 and the vectors comprising these, and method of treating other autoimmune diseases, the underlying U.S. patent estate has been further strengthened for the protection of the company's intellectual property related to further development and potential commercialization of HCW9302, a best-in-class IL-2-based immunotherapeutic for the treatment of autoimmune diseases. The company continues to extend protection of its broad rights for treatments for all indications with respect to HCW9302 built on the foundation of its worldwide, perpetual, fully paid-up, royalty-free, exclusive license rights for this compound. The Phase 1 dose-escalating clinical study evaluating HCW9302 as monotherapy in patients with alopecia areata is on track for completion in Q4 2026, and continues to be well tolerated with no dose-limiting toxicities. A preliminary readout of the first two dose cohorts is encouraging, with patients diagnosed with alopecia areata showing positive response after a single dose of monotherapy at the 3 micrograms/kg dose level.
Selling Stockholders Plan to Sell 1.24M Shares of Common Stock
This filing relates to the offer and sale from time to time by the selling stockholders of up to 1.24M shares of common stock. The company is not selling any shares under this prospectus and will not receive any of the proceeds from the sale of shares by the selling stockholders.
関連記事
- CPI Report and the Stock Market: How to Read October 2026 Inflation Data Before the Fed DecidesOctober 2026 CPI lands Nov 10 with no year-over-year number and Fed hike odds near 80%. Learn how to read CPI, which stocks react, and how to plan for it.
- Are You Buying NVIDIA’s Earnings or Its CEO’s Perfect Image?An Alphio analysis of NVIDIA’s share-price timeline, operating results, governance uncertainty and upcoming earnings.
- Stock Market After the 2026 Midterms: What a Democratic Congress Means for InvestorsDemocrats swept Congress in the 2026 midterms. See how stocks reacted, what history says about post-midterm returns, and which sectors face new risks.
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。